Somerset Hunterdon Warren Psychological Association
FRIDAY OCTOBER 23, 2020
“OPIOID ADDICTION AND ITS TREATMENT: WHAT EVERY PSYCHOLOGIST NEEDS TO KNOW”
Presented by: Arnold M. Washton, Ph.D.
Three (3) Continuing Education (CE) Credits for Psychologists: this includes one (1) Opioids CE credit required for NJ Psychologists every 2 Years. CE payment and evaluation survey completed online.
CE Fees: NJPA: Sustaining Members-Free, NJPA Members-$15, NJPA Non-Members- $25.
ZOOM REGISTRATION and Welcome 9:00AM-12:15PM
Presentation/Q&A (Half Hour Break – 10:30)
Location: ZOOM – MEETING ID and PASSWORD will be emailed following registration
Workshop Cost: $25 SHPA members / $35 non-members
About the Speaker: Arnold M. Washton, Ph.D., is a psychologist and book author specializing in the treatment of substance use and other behavioral health problems since 1975. He is currently Co-Founder of The Washton Group, a private practice in Princeton NJ and midtown Manhattan. Dr. Washton has served as Clinical Professor of psychiatry at NYU School of Medicine, as director of several nationally recognized addiction treatment programs, and as consultant to professional sports teams, government agencies, media organizations, and major corporations. He has been a recipient of research grants from the National Institute on Drug Abuse and has served as substance abuse advisor to the U.S. Food and Drug Administration, special committees of The U.S. Senate and House of Representatives, and the American Psychological Association. Dr. Washton has authored over 100 journal articles and nine books.
Workshop Abstract: The epidemic use of prescription painkillers and other opioids has resulted in a tidal wave of overdose deaths, emergency room visits, and treatment admissions. Because an increasing number of opioid users seek professional help from office-based mental health practitioners, it is imperative for all psychotherapists to understand the relevant pharmacology of opioid drugs and know how to properly assess, engage, treat, and/or refer these clients whether or not substance use is a primary or presenting complaint. This presentation will provide an overview of the relevant pharmacology of opioid drugs, clinical assessment/diagnostic strategies, medications for treating opioid dependence (including buprenorphine and naltrexone), how to coordinate care with medication prescribers, and the elements of an integrated client-centered approach that incorporates a variety of evidence-based psychotherapeutic and pharmacological interventions. Lecture material will include case vignettes to highlight specific clinical considerations and techniques.
Diversity Considerations- The evidence-based treatment approaches are attractive to a diverse client population as it advocates an individualized approach that places a high priority on listening to, collaborating with, and meeting clients "where they are" instead of requiring them to adhere to pre-formulated agendas. Harm reduction respects individual differences including cultural considerations and the rights of clients to choose their own treatment goals. Research indicates that harm reduction strategies have high acceptance rates among minority clients especially when cultural sensitivity and community support issues are properly considered. Learning Objectives: As a result of attending this presentation, participants will be able to: 1. Summarize the prevalence of opioid use and its public health consequences across different age, gender, and racial populations. 2. List the most common opioid drugs including naturally-occurring and synthetic substances. 3. Explain the categorization of opioids as agonists or antagonists based on their action at opioid receptor sites in the CNS. 4. Summarize the physiological/medical effects of opioids and interaction with other drugs. 5. Explain the developmental course of opioid use, dependence, and withdrawal. 6. Describe the subjective (mood-altering) effects of opioids that make them so compelling and addictive. 7. List the most effective medications for treating opioid dependence, indications for their use, and how to optimize collaboration with prescribing physicians. 8. Summarize the essential features of assessment and diagnosis of opioid use disorders. 9. Describe the most salient motivational and relapse prevention strategies. 10. Summarize the key issues to be addressed in ongoing psychotherapy and relapse prevention. Target Audience: Psychologists Program Sophistication: Intermediate: Some basic knowledge of the specific content is required Commercial support: Dr. Washton does not have any commercial support and/or conflict for interest for this program. ADA
Accommodations: Not applicable because this presentation is on Zoom. Register: and pay at shwpa.org or contact Mark Aronson by October 19, 2020 firstname.lastname@example.org, Or send a check payable to SHWPA to: Mark Aronson PO Box 283 Pluckemin, NJ 07978-0283 Registration cancellations made more than 48 hours in advance of the program will be refunded (less administrative fees). This workshop is co-sponsored by NJPA and the Somerset Hunterdon Psychological Association. NJPA is approved by the American Psychological Association to offer continuing education for psychologists. NJPA maintains responsibility for the program and its content.
The Somerset Hunterdon Psychological Association. All Rights Reserved.